Biogen reported $2.54B in Sales Revenues for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Abbvie ABBV:US USD 15.12B 309M
Acorda Therapeutics ACOR:US USD 31.47M 2.04M
Amgen AMGN:US USD 6.84B 187M
Biogen BIIB:US USD 2.54B 35.5M
Bluebird Bio BLUE:US USD 71K 1.45M
Bristol Myers Squibb BMY:US USD 11.41B 188M
Eli Lilly And LLY:US USD 7.3B 360.2M
Esperion Therapeutics ESPR:US USD 18.82M 162K
Gilead Sciences GILD:US USD 7.39B 347M
Merk MRK:US USD 13.83B 1.13B
Neurocrine Biosciences NBIX:US USD 412M 24.1M
Novartis NOVN:VX USD 13B 159M
Pfizer PFE:US USD 24.29B 1.65B
Regeneron Pharmaceuticals REGN:US USD 3.41B 478.2M
Sangamo Biosciences SGMO:US USD 27.23M 770K
Seattle Genetics SGEN:US USD 528.15M 17.85M
Teva Pharmaceutical TEVA:IT USD 3.88B 289M
Ultragenyx Pharmaceutical RARE:US USD 103.35M 12.64M
Vertex Pharmaceuticals VRTX:US USD 2.3B 31.6M
YTE INCY:US USD 926.7M 103.4M